Sirolimus Tablet, Film Coated
Product Images NDC 60687-902

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Sirolimus (NDC 60687-902). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

0.5 mg Sirolimus Tablet Blister.jpg (0.5 mg Sirolimus Tablet Blister.jpg)

0.5 mg Sirolimus Tablet Blister.jpg (0.5 mg Sirolimus Tablet Blister.jpg)
Label images for sirolimus 0.5 mg film-coated oral tablets. Each label shows the product name, strength, dosage form, manufacturer American Health Packaging, lot number 1234567, and expiration date 2025-06-12. The label also includes barcodes and the NDC 60687-902.*
FDA Label Image

0.5 mg Sirolimus Tablets Carton.jpg (0.5 mg Sirolimus Tablets Carton.jpg)

0.5 mg Sirolimus Tablets Carton.jpg (0.5 mg Sirolimus Tablets Carton.jpg)
Label for Sirolimus Tablets 0.5 mg oral film-coated tablets by American Health Packaging. The label states the NDC 60687-902-21 with a package count of 30 tablets (3 x 10). It includes usage instructions, storage conditions, pharmacist dispensing information, and a QR code for the current Medication Guide and prescribing information.*
FDA Label Image

Ahp90221

Ahp90221
sirolimus 0.5 mg oral film-coated tablet shown front and back. The front side is yellow with the imprint '1' in black. The back side is plain yellow without any markings. Manufactured by American Health Packaging.*
FDA Label Image

Image (B28dd501 1384 4376 Be15 Ce15c0d22439 01)

Image (B28dd501 1384 4376 Be15 Ce15c0d22439 01)
Chemical structure of sirolimus, showing its complex molecular arrangement of atoms and bonds typical of a macrolide immunosuppressant compound.*
FDA Label Image

Figure 1 (B28dd501 1384 4376 Be15 Ce15c0d22439 02)

Figure 1 (B28dd501 1384 4376 Be15 Ce15c0d22439 02)
A line graph showing the FEV1 (liters) over 24 months, divided into a Treatment Phase and Observation Phase, comparing Sirolimus and Placebo groups. The graph includes error bars and subject numbers for each group at various time points, illustrating differences in lung function between Sirolimus and Placebo over time.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.